Plenty of folks have been using GLP-1s — generic versions of popular weight loss drugs such as Ozempic and Zepbound — to jump-start their health journeys lately. But those folks could be in for bad ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Weight loss drugs have surged in popularity. But Gov. Ned Lamont wants CT’s Medicaid program to discontinue covering them for ...

Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Lady Gaga is set to take on Chappell Roan for Number 1 this week – Abracadabra (2) is less than 1,400 chart units away from Pink Pony Club (1), which became the first UK chart-topper for pop ...

Ozempic (semaglutide) is a prescription drug used for certain conditions in people with type 2 diabetes ... of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists.

Novo currently markets its GLP-1 treatments, which both contain the active ingredient semaglutide, as Wegovy for weight loss and Ozempic for type II diabetes. However ... its own GLP-1 medicines in ...

GLP-1 medications continue to surge in popularity, offering effective solutions for weight management, Type 2 diabetes, and other emerging indications. While these drugs show significant clinical ...

The researchers found that compared with nonusers, patients using GLP-1 RAs were more likely to be female (59.0 versus 56.4 percent) and diagnosed with both obesity and diabetes (47.5 versus 6.8 ...

researchers reviewed the medical records of more than 18,000 kidney transplant recipients with diabetes between 2013 and 2020. Of those, more than 1,900 had been prescribed a GLP-1 drug.

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use; 3.9 vs 1.8 per 1000 person-years. HealthDay News — Glucagon ...